The selective estrogen receptor-β agonist biochanin A shows vasculoprotective effects without uterotrophic activity

Abstract

The ERbeta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. Because hormone therapy may have cancer-promoting side effects, administration of ERbeta-selective agents might be alternatively used to reduce the risk of cardiovascular disease in postmenopausal women.